Hospital

Pharmacy Times speaks with Helen Latimer, MPH, to discuss the advancement of HRR genetic testing equity in metastatic prostate cancer.

Hemophilia management is shifting from traditional intravenous therapies toward subcutaneous agents.

Pharmacy Times speaks with Jeff Goad, PhD, MPH, a professor of pharmacy practice at Chapman University, on the role pharmacists play during outbreaks or rising measles cases.

GLP-1 receptor agonists could influence endometrial cancer prevention, obesity management, fertility preservation, and molecularly guided treatment strategies in gynecologic oncology.

Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.

Pharmacy Times speaks with Jeff Goad, PhD, MPH, about the biggest misconceptions surrounding measles and the MMR vaccine, as well as the serious symptoms pharmacists believe patients should never ignore.

Jessica Geiger, PharmD, weighs ketamine in palliative care—pain relief, opioid-sparing evidence, stigma, and safety considerations for hospice patients.

Perioperative durvalumab and tremelimumab plus neoadjuvant enfortumab vedotin improves survival in muscle-invasive bladder cancer.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Pharmacy Times interviews Sarah Spark, MHA, MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of real-world oncology data to better support clinical decision-making, research, and patient outcomes.

FACT-accredited centers vs nonaccredited centers may influence CAR T-cell therapy outcomes.

The drug is currently under priority review by the FDA with a final decision expected by June 16, 2026.

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

Emerging data support less intensive antithrombotic strategies for LVADs that could reduce bleeding complications without compromising thromboembolic protection.

The findings emphasize the growing role of precision oncology and integrated EHR infrastructure in expanding access to targeted therapies.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

Pharmacy Times interviews Helen Latimer, MPH, about new real-world data examining racial disparities and evolving trends in HRR genetic testing among patients with metastatic prostate cancer and the implications for equitable access to precision oncology care.

Natalie Bellini, DNP, FNP-BC, BC-ADM, explains why continuous glucose monitor (CGM) persistence so often breaks down after initiation and how pharmacists can intervene at the point of dispensing.

Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.

The FDA approved 2 new indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer, expanding its use in both neoadjuvant and adjuvant settings.

Minimizing sedation, cognitive impairment, and addiction risk are key priorities.

Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.

FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.

Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Pharmacists must balance the lifesaving automation of advanced technology with the harsh reality of a high-cost, high-risk transition.

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.